



06-16-06

1636 IFW

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

10

Application Number

10/068,664

Filing Date

02/06/2002

First Named Inventor

Chuan LI

Art Unit

1636

Examiner Name

James S. Ketter

Attorney Docket Number

**ENCLOSURES**

(Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

Remarks

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name			
Signature	<i>Chuan Li</i>		
Printed name	Chuan LI		
Date	6/15/06	Reg. No.	

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature	<i>Chuan Li</i>		
Typed or printed name	Chuan LI	Date	6/15/06

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Amendments to application: DE NOVO SYNTHESIZED PLASMID, METHODS OF MAKING AND USE THEREOF

Applicant Name: Chuan Li

Date: June 15, 2006

Application/Control Number: 10/068,664

Art Unit: 1636

**a.) Introductory Comments**

These are amendments of application (Application Number: 10/068,664) filed on February 6, 2002. The plasmids disclosed in the application are novel plasmids. Each of them can be used independently. Some of these plasmids or their derivatives were used together to make other plasmids and DNA fragments or to express recombinant proteins. It has not been shown if all these plasmids can be used together. The possibility that all disclosed plasmids can be used together cannot be ruled out. In addition, all disclosed plasmids have similar design, modes of operation and effects. For example, all these plasmids are designed to have a replication origin and a selection marker. Same adaptor sequences are used in each plasmid to link a replication origin and a selection marker sequences together. The complete sequences of a plasmid are different than those of another plasmid. However two plasmids may share a same replication origin or a selection marker. All plasmids are made based on the design that a plasmid can be made with a replication origin and a selection marker. They are all made by same experiment procedures.

New claims are being submitted as part of these amendments; these claims are submitted to be patentable over the art of record in the parent cases for the following reasons.

1. All Plasmids claimed in new claims 26, 31, and 36 are new plasmids.
2. All Plasmids claimed in new claims 26, 31, and 36 are useful. They are used in making other plasmids, DNA vectors, and cell strains. All these resulting products are useful in various biomedical applications.
3. All Plasmids claimed in new claims 26, 31, and 36 are not obvious. Each of the claimed plasmids is smaller in size than any plasmid containing same replication

origin and selection marker reported in the previous arts. Sequences of unknown or undesirable functions are eliminated from the claimed plasmids. These junk sequences contribute to cellular energy drain and are detrimental to future plasmid usages and applications. Eliminating these junk sequences will allow host cells grow better and more useful sequences to be put in these plasmids. All plasmids have cloning or size limit. The less junk sequences a plasmid contains, the more useful sequences may be put in the plasmid. In addition to the small size, many other features presented in previous communications indicate that these claimed plasmids are not obvious.

In conclusion, the disclosed plasmids are new, useful and unobvious. It is neither anticipated nor obvious over any prior teaching or any prior arts or combination of them. Therefore the re-written claims are submitted that patentable subject matter is clearly present. If the examiner agrees but does not feel that the present claims are technically adequate, applicant respectfully requests that the examiner write acceptable claims pursuant to MPEP 707.07(j).